Masked inv dup(22)(q11.23), tetrasomy 8 and trisomy 19 in a blast crisis-chronic myeloid leukemia after interrupted Imatinib-treatment
© Wafa et al. 2015
Received: 26 November 2015
Accepted: 17 December 2015
Published: 23 December 2015
The Philadelphia (Ph) chromosome, or derivative chromosome 22 [der(22)], is a product of the reciprocal translocation t(9;22). It is the hallmark of chronic myelogenous leukemia (CML). It results in juxtaposition of the 5’ part of the BCR gene on chromosome 22 to the 3’ part of the ABL1 gene on chromosome 9. During CML progression 60–80 % of the cases acquire additional genetic changes. Blast crisis (BC) is characterized by the rapid expansion of a population of differentiation arrested blast cells (myeloid or lymphoid cells population), often presenting with secondary chromosomal abnormalities. Here we report an unusual CML-BC case with acquired secondary chromosomal aberrations observed after the patient had to interrupt a successful Imatinib treatment for overall 16 months.
A complete cytogenetic and molecular cytogenetic analysis were performed and application of molecular genetic methods such as reverse transcription polymerase chain reaction (RT-PCR) finally characterized a complex karyotype including an inv dup(22)(q11.23), tetrasomy 8 and trisomy 19.
Here we report the first case of a BC after successfully initiated and suddenly interrupted Imatinib treatment. Changes present after such an instant indicate for a rapid progression after Imatinib is no longer suppressing the disease.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the presence of Philadelphia (Ph) chromosome or also is called a derivative chromosome 22 [der(22)]. The latter is found as sole aberration in more than 90 % of the early chronic phase (CP) CML cases and it is due to a reciprocal translocation t(9;22)(q34.1;q11.2). This rearrangement involves the breakpoint cluster region (BCR) gene 22q11.2 and the c-Abelson proto-oncogene (ABL1) gene in 9q34, generating a chimeric BCR-ABL gene that encodes a constitutively activated protein tyrosine kinase. The kinase activity of BCR-ABL is essential for the pathogenesis of CML .
Additional genetic changes occur in less than 10 % of CML cases at diagnosis; other genetic changes are detectable in 60-80 % of the cases in advanced disease [accelerated phase (AP) and blast crisis (BC)] . The correct identification of such abnormalities is important for diagnosis of the diseases determined by the WHO Tumor Classification  and for treatment purposes. The first therapeutic choice, tyrosine kinase inhibitors, has shown great therapeutic efficacy .
Imatinib mesylate (IM = Glivec, formerly called STI571) is a chemically designed drug able to block BCR/ABL1 tyrosine kinase activity and is successfully used as a first-line therapy for all CML patients . It has significantly improved the prognosis especially for newly diagnosed CML-CP patients, in which the complete hematologic response rate was more than 90 %, and the complete cytogenetic response rate 70-80 %. However, IM resistance has emerged as an important clinical challenge. Multiple factors may contribute to IM resistance including mutations of BCR-ABL1 kinase domain, BCR-ABL1 amplification or enhanced expression rates, clonal evolution, and decrease in imatinib bioavailability or cell exposure . Amplification can be determined by fluorescence in situ hybridization (FISH) or comparative genome hybridization (CGH), while other aforementioned developments are difficult to monitor.
Here we presented a new CML-BC case with complex karyotypic changes including an inv dup(22)(q11.23) in a patient with an interrupted IM treatment; to the best of our knowledge the outcome of such a case was not previously reported.
In June 2011 a 62-year-old Syrian male was diagnosed as suffering from CML. Physical examination revealed splenomegaly, which was the indicative symptom. Routine peripheral blood test showed elevated white blood cells (WBC) of 170.1 × 109/l (43.2 % neutrophils, 7.9 % lymphocytes, 11.2 % monocytes, 28.1 basophiles, and 9.6 % eosinophiles), red blood cell (RBC) count was 3.05 × 106/mm3, hemoglobin level was 6.1 g/dl and the platelet count was 1,039 × 109/l. The patient was diagnosed as CML-AP according to WHO recommendations. The patient did not receive any previous treatment.
The patient was referred for a second time in July 2012 and was successfully treated with IM (400 mg/day) for 13 months. The more recent routine peripheral blood test was: WBC 5.3 × 109/l (52.1 % neutrophils, 34.8 % lymphocytes, 10.5 % monocytes, 0.5 basophiles, and 2.1 % eosinophiles), RBC count was 2.98 × 106/mm3. The platelet count was 203 × 109/l and the hemoglobin level was 10.9 g/dl. Serum lactate dehydrogenase value (LDH) was 512 U/l (normal level <460 U/l).
The patient was referred for a third time in May 2014 after he stopped IM treatment for 16 months due to political situation in his home country. WBC was then 1,334.0 × 109/l (92 % of cells were blasts), red blood cell (RBC) count was 1.91 × 106/mm3, hemoglobin level was 6.1 g/dl and the platelet count was 56 × 109/l. The patient was diagnosed as CML-BC according to WHO recommendations, in a high Sokal risk of 2,594 (0.8–1.2), high Hasford (Euro) risk of 6039 (>1,480), and Etous probability of no complete cytogenetic response (CCgR) at 18 months was 11 %. Later the patient was lost during follow-up.
dup(22)(::q11.23- > p13::p13-
dup(22)(:q11.23- > p13::p13-
dup(22)(:q11.23- > p13::p13-
According to the literature, BC of CML may be myeloid or lymphoid. Approximately 15–20 % of patients in BC retain the Ph + cell population unaltered, whereas 80–85 % of the cases undego karyotypic evolution . The most common secondary chromosomal aberrations in addition to a Ph-chromosome are +8, +Ph, i(17q) and +19. Other chromosomal aberrations are less frequent, as -Y, +21, +17, −7, and −17 [1, 6]. Hyperdiploidy is not common in CML cases , however it is a common finding in advanced phase-CML patients [6, 8], and it was already reported in one CML-CP patient as a secondary chromosomal aberration after IM therapy .
The der(22) inv dup(22)(q11.2)t(9.22)(q34;q11.2) is an uncommon event in CML-advanced phase. However, this chromosomal aberration was observed in 6 cases before (the majority were CML-advanced phase), and it was product of a der(22)t(9;22)(q34;q11.2); the BCR/ABL1 fusion remained on such inv dup(22) derivatives [10-13]. In the present case, we noted an inv dup(22)(q11.23) without presence ABL1 signal on derivative 22. To our knowledge, BC characterized by a inv dup(22)(q11.23) without presence ABL1 signal on inv dup(22) associated with tetrasomy 8 and trisomy 19 has not been reported together in CML, yet . Maybe submicroscopic structures of DNA-sequences in chromosome 22 are herfore responsible  However, tetrasomy 8 is not a rare event in advanced phase-CML; more than 50 such cases are listed in Mitelman Database .
Clinical resistance by BCR-ABL1 amplification mechanism is uncommon, but not a really rare event in CML resistance to treatment. Amplification of the Ph chromosome on conventional karyotyping may present as double Ph, dicentric Ph, double minutes, or masked Ph and inverted duplication of Ph [13, 16]. However, inverted duplication is unique structure and it is related to a DNA amplification event, which led to increased expression of bcr-abl protein [17, 18]. Thus, the inv dup(22) derivative is not easily connected with IM-resistance.
CML patients in AP and myeloid BC treated with 400 or 600 mg of IM can show major cytogenetic response [9, 10, 19]. However, our patient achieved only a minor cytogenetic response followed 13 months of IM treatment. Aberrations like inv dup(22)(q11.23) without presence ABL1 signal on inv dup(22) associated with tetrasomy 8 and trisomy 19 were noted after the reported patient stopped IM treatment involuntarily for overall 16 months. Thus, it is unclear, still unlikely, that such kind of karyotypic changes might have been seen in this patient in connection with IM-resistance development. In conclusion the present case is one of the rare examples, where infortune political circumstances lead to unintentional interruption of a successful IM-treatment in a Syrian CML-patient. It is thus a unique example for which cytogenetic changes may appear during 16 month interruption of IM-treatment. Trisomy 8 and 19 have earlier been reported as secondary events in untreated or treated CML in BC. The inv dup(22)(q11.23) seen here may be a secondary finding appearing after interrupted IM-treatment.
Materials and Methods
Chromosome analysis applying GTG-banding according to standard procedures  was performed prior IM treatment. 20 metaphase cells derived from unstimulated bone marrow culture were analyzed. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN 2013) .
Fluorescence in situ hybridization (FISH) using the LSI BCR/ABL dual color dual fusion translocation probe (Abbott Molecular/Vysis, Des Plaines, IL, USA), alpha satellite probes for chromosomes 14 and 22 (Qbiogene, MP Biomedicales, Santa Ana, CA, USA) were applied together with whole chromosome painting (WCP) probe for chromosomes 9 and 22 (MetaSystems, Altlussheim, Germany) according to manufacturer's instructions . Also a multicolor banding probe (MCB) sets based on microdissection derived region-specific libraries for chromosome 22 was applied as previously described . A minimum of 10 metaphase spreads was analyzed, using a fluorescence microscope (AxioImager.Z1 mot, Carl Zeiss Ltd., Hertfordshir, UK) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes plus the counterstain DAPI (4',6- diamino-2-phenylindole). Image capture and processing were performed using an ISIS imaging system (MetaSystems, Altlussheim, Germany).
Reverse transcriptase-polymerase chain reaction (RT-PCR) and for BCR/ABL1 fusion transcripts
Total RNA extracted from peripheral blood sample using the InviTrap RNA kit (Invitek, Berlin, Germany) according to the manufacturer’s recommendations. cDNA was prepared from 5 μg of total RNA with the Genequality BCR-ABL1 kit (AB Analitica, Padova, Italy) and BCR-ABL1 fusion transcript was performed according to the manufacturer’s instructions (AB Analitica, Padova, Italy).
Written informed consent was obtained from the patient for publication of this Case Report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Prof. I. Othman, the Director General of Atomic Energy Commission of SYRIA (AECS) and Dr. N. Mirali, Head of Molecular Biology and Biotechnology Department for their support. This work was supported by the AECS.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.PubMedView ArticleGoogle Scholar
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of tumors of haematopoietic andlymphoid tissues. 4th ed. Geneva: IARC; 2008. p. 439.Google Scholar
- Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendationsfor the management of chronic myeloid leukemia: 2013. Blood. 2013;122:871–84.View ArticleGoogle Scholar
- Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. RIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.PubMedView ArticleGoogle Scholar
- Apperlley JF. Part1: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018–29.View ArticleGoogle Scholar
- Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010–4022.PubMedView ArticleGoogle Scholar
- Belurkar S, Manohar C, Kurien A. Chronic myeloid leukemia with hyperdiploidy: a case report with review of literature. Indian J Med Sci 2013;67:188–192.PubMedView ArticleGoogle Scholar
- Roland B, Blahey Walter B. A case of near triploidy in chronic myelogenousleukemia. Cancer Genet Cytogenet 2000;121:96–98.PubMedView ArticleGoogle Scholar
- Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118:6760.PubMedView ArticleGoogle Scholar
- Sirulink A, Silver RT, Najfeld V. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571. Leukemia. 2001;15:1795–7.PubMedView ArticleGoogle Scholar
- Mohammed M, Shin S, Deng S, Ford J, Paquette RL, Sawyers CL. BCR/ABL gene amplification: a possible mechanism of drug resistancein patients treatedwith an ABL specific kinase inhibitor. Blood. 2000;96:Abstr. 1486.Google Scholar
- Phan CL, Chang KM, Noor Megat Baharuddin PJ, Zakaria Z. Complex Chromosomal Abnormalities In a Case of Imatinib Resistant Chronic Myelogenous Leukemia. J Association of Genetic Technologists. 2010;36:61–4.Google Scholar
- Phan CL, Megat Baharuddin PN, Chin LP, Zakaria Z, Yegappan S, Sathar J, et al. Amplification of BCRABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2008;180:60–4.PubMedView ArticleGoogle Scholar
- González García JR, Cruz MD, Gutiérrez CB. Are submicroscopic chromosomal inversions predisposing factors for the t(9;22)(q34;q11.2) translocation in chronic myeloid leukemia? Mol Cytogenet. 2015;8:14.Google Scholar
- Mitelman Database of Chromosome Aberrations in Cancer (2015). Mitelman F, Johansson B and Mertens F (Eds.), http://cgap.nci.nih.gov/Chromosomes/Mitelman" [last accessed 10.02.2015].
- Fugazza G, Garuti A, Marchelli S, Miglino M, Bruzzone R, Gatti AN, et al. Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005;163:173–5.PubMedView ArticleGoogle Scholar
- Passananti C, Davies B, Ford M, Fried M. Structure of an inverted duplication formed as a first step in a gene amplification event: implications for a model of gene amplification. EMBO J. 1987;6:1697–703.PubMedPubMed CentralGoogle Scholar
- Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR/ABL gene mutation or amplification. Science. 2001;293:876–80.PubMedView ArticleGoogle Scholar
- Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42.PubMedView ArticleGoogle Scholar
- AL-achkar W, Wafa A, Nweder MS: A complex translocation t(5;9;22) in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia. J Exp Clin Cancer Res. 2007;26:411–5.Google Scholar
- Shaffer LG, McGowan-Joran J, Schmid MS. ISCN 2013: An International System of Human Cytogenetic Nomenclature. Unionville, CT, USA: S. Karger Publications, Inc; 2013.Google Scholar
- Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, et al. Microdissection based high resolution multicolorbanding for all 24 human chromosomes. Int J Mol Med. 2002;9:335–9.PubMedGoogle Scholar